EA201791936A1 - Рекомбинантные конструкции glut1 аденоассоциированного вирусного вектора и способы восстановления экспрессии glut1 на их основе - Google Patents
Рекомбинантные конструкции glut1 аденоассоциированного вирусного вектора и способы восстановления экспрессии glut1 на их основеInfo
- Publication number
- EA201791936A1 EA201791936A1 EA201791936A EA201791936A EA201791936A1 EA 201791936 A1 EA201791936 A1 EA 201791936A1 EA 201791936 A EA201791936 A EA 201791936A EA 201791936 A EA201791936 A EA 201791936A EA 201791936 A1 EA201791936 A1 EA 201791936A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- glut1
- relates
- methods
- present
- associated virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
Настоящее изобретение относится к рекомбинантным конструкциям Glut1 аденоассоциированного вирусного вектора (AAV) и способам восстановления экспрессии Glut1 на их основе у млекопитающих с дефицитом Glut1. В некоторых вариантах реализации изобретения rAAV дополнительно содержит β-актиновый промотор курицы, причем rAAV способен проникать сквозь гематоэнцефалический барьер (ГЭБ). В некоторых вариантах реализации настоящее изобретение относится к композиции, содержащий любой из рекомбинантных AAV, описанных в настоящем описании. В некоторых вариантах реализации настоящее изобретение относится к набору, содержащему емкость, которая содержит композицию, описанную в настоящем описании. В некоторых вариантах реализации настоящее изобретение относится к способам восстановления транспорта Glut1 в ГЭБ субъекта, включающим введение субъекту эффективного количества любого из рекомбинантных векторов AAV, описанных в настоящем документе. В некоторых вариантах реализации настоящее изобретение относится к способу лечения синдрома дефицита Glut1 у субъекта, нуждающегося в этом.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562130899P | 2015-03-10 | 2015-03-10 | |
PCT/US2016/021810 WO2016145217A1 (en) | 2015-03-10 | 2016-03-10 | Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201791936A1 true EA201791936A1 (ru) | 2018-01-31 |
EA201791936A8 EA201791936A8 (ru) | 2018-11-30 |
EA036051B1 EA036051B1 (ru) | 2020-09-18 |
Family
ID=56879055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791936A EA036051B1 (ru) | 2015-03-10 | 2016-03-10 | РЕКОМБИНАНТНЫЙ АДЕНОАССОЦИИРОВАННЫЙ ВЕКТОР (rAAV), СПОСОБНЫЙ ПРОНИКАТЬ СКВОЗЬ ГЕМАТОЭНЦЕФАЛИЧЕСКИЙ БАРЬЕР (ГЭБ), И ЕГО ПРИМЕНЕНИЕ ДЛЯ ВОССТАНОВЛЕНИЯ ЭКСПРЕССИИ Glut1 |
Country Status (19)
Country | Link |
---|---|
US (2) | US20180042991A1 (ru) |
EP (1) | EP3268024B1 (ru) |
JP (3) | JP2018509164A (ru) |
KR (1) | KR20180016722A (ru) |
CN (1) | CN107635575A (ru) |
AU (1) | AU2016229000B2 (ru) |
BR (1) | BR112017019294A2 (ru) |
CA (1) | CA2978917A1 (ru) |
CL (1) | CL2017002282A1 (ru) |
CO (1) | CO2017010149A2 (ru) |
DK (1) | DK3268024T3 (ru) |
EA (1) | EA036051B1 (ru) |
ES (1) | ES2836258T3 (ru) |
HU (1) | HUE052577T2 (ru) |
IL (2) | IL282053B2 (ru) |
MX (2) | MX2017011615A (ru) |
PT (1) | PT3268024T (ru) |
SG (1) | SG11201707116QA (ru) |
WO (1) | WO2016145217A1 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017005834A (es) | 2014-11-05 | 2017-11-17 | Voyager Therapeutics Inc | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. |
JP6996728B2 (ja) * | 2016-01-07 | 2022-01-17 | 学校法人自治医科大学 | グルコーストランスポーター1発現用アデノ随伴ウイルスベクター |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
EP3790394A4 (en) * | 2018-05-08 | 2022-07-27 | Rutgers, the State University of New Jersey | POLYMERIZING PROTEINS AAV-COMPATIBLE LAMININ LINKER |
KR20210068068A (ko) * | 2018-09-28 | 2021-06-08 | 보이저 테라퓨틱스, 인크. | 조작된 프로모터를 갖는 프라탁신 발현 구축물 및 그의 사용 방법 |
JP7284833B2 (ja) | 2019-05-13 | 2023-05-31 | ディーエヌエー ツーポイントオー インク. | 特性を変えるための人工マイクロrnaを用いた哺乳類細胞の改変及びその生産物の組成物 |
CN114555814A (zh) * | 2019-09-13 | 2022-05-27 | 罗特格斯新泽西州立大学 | Aav相容的层粘连蛋白-连接子聚合蛋白 |
CA3174939A1 (en) * | 2020-05-01 | 2021-11-04 | Nikolay ZHUKOVSKY | Treatment and/or prevention of a disease or a syndrome related to a virus infection |
CA3185234A1 (en) * | 2020-07-09 | 2022-01-13 | Dorota Danuta KLYSZ | Immune cells with increased glycolytic flux |
AU2021321412A1 (en) * | 2020-08-05 | 2023-04-06 | Spacecraft Seven, Llc | Adeno-associated viral vector for GLUT1 expression and uses thereof |
AU2021320902A1 (en) | 2020-08-07 | 2023-04-06 | Spacecraft Seven, Llc | Plakophilin-2 (PKP2) gene therapy using AAV vector |
WO2022051627A2 (en) * | 2020-09-04 | 2022-03-10 | Dna Twopointo Inc. | Modifications of mammalian cells using artificial micro-rna to alter their properties and the compositions of their products |
WO2023154763A2 (en) * | 2022-02-08 | 2023-08-17 | Spacecraft Seven, Llc | Adeno-associated viral vector for glut1 expression and uses thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
WO1998010088A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
WO2004096841A1 (en) * | 2003-05-02 | 2004-11-11 | Centre National De La Recherche Scientifique | Glut-1 as a receptor for htlv envelopes and its uses |
ES2648241T3 (es) | 2003-09-30 | 2017-12-29 | The Trustees Of The University Of Pennsylvania | Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos |
ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
WO2008134632A1 (en) * | 2007-04-26 | 2008-11-06 | President And Fellows Of Harvard College | Wnt ligands involved in blood-brain barrier development and uses therefor |
WO2010071832A1 (en) * | 2008-12-19 | 2010-06-24 | Nationwide Children's Hospital | Delivery of polynucleotides across the blood brain barrier using recombinant aav9 |
US9610363B2 (en) * | 2009-04-16 | 2017-04-04 | President And Fellows Of Harvard College | Methods for inhibiting starvation of a cell |
DK2826860T3 (en) * | 2010-04-23 | 2018-12-03 | Univ Massachusetts | CNS targeting AAV vectors and methods for their use |
EP2394667A1 (en) * | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
-
2016
- 2016-03-10 CA CA2978917A patent/CA2978917A1/en active Pending
- 2016-03-10 AU AU2016229000A patent/AU2016229000B2/en active Active
- 2016-03-10 SG SG11201707116QA patent/SG11201707116QA/en unknown
- 2016-03-10 EP EP16762530.0A patent/EP3268024B1/en active Active
- 2016-03-10 EA EA201791936A patent/EA036051B1/ru unknown
- 2016-03-10 US US15/556,412 patent/US20180042991A1/en not_active Abandoned
- 2016-03-10 CN CN201680025266.9A patent/CN107635575A/zh active Pending
- 2016-03-10 JP JP2017548205A patent/JP2018509164A/ja active Pending
- 2016-03-10 HU HUE16762530A patent/HUE052577T2/hu unknown
- 2016-03-10 PT PT167625300T patent/PT3268024T/pt unknown
- 2016-03-10 DK DK16762530.0T patent/DK3268024T3/da active
- 2016-03-10 WO PCT/US2016/021810 patent/WO2016145217A1/en active Application Filing
- 2016-03-10 ES ES16762530T patent/ES2836258T3/es active Active
- 2016-03-10 MX MX2017011615A patent/MX2017011615A/es unknown
- 2016-03-10 IL IL282053A patent/IL282053B2/en unknown
- 2016-03-10 KR KR1020177028554A patent/KR20180016722A/ko not_active Application Discontinuation
- 2016-03-10 BR BR112017019294A patent/BR112017019294A2/pt active Search and Examination
-
2017
- 2017-09-03 IL IL254286A patent/IL254286B/en active IP Right Grant
- 2017-09-08 MX MX2023001213A patent/MX2023001213A/es unknown
- 2017-09-08 CL CL2017002282A patent/CL2017002282A1/es unknown
- 2017-10-05 CO CONC2017/0010149A patent/CO2017010149A2/es unknown
-
2020
- 2020-11-19 US US16/952,801 patent/US20210069292A1/en active Pending
-
2021
- 2021-03-01 JP JP2021032174A patent/JP2021097689A/ja active Pending
-
2023
- 2023-08-17 JP JP2023133147A patent/JP2023144087A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN107635575A (zh) | 2018-01-26 |
DK3268024T3 (da) | 2020-12-07 |
KR20180016722A (ko) | 2018-02-19 |
EP3268024A1 (en) | 2018-01-17 |
CO2017010149A2 (es) | 2018-02-28 |
AU2016229000B2 (en) | 2021-11-04 |
IL254286A0 (en) | 2017-10-31 |
PT3268024T (pt) | 2020-12-09 |
HUE052577T2 (hu) | 2021-05-28 |
JP2021097689A (ja) | 2021-07-01 |
IL282053B2 (en) | 2023-03-01 |
AU2016229000A1 (en) | 2017-09-21 |
JP2023144087A (ja) | 2023-10-06 |
CL2017002282A1 (es) | 2018-04-13 |
IL254286B (en) | 2021-04-29 |
EA036051B1 (ru) | 2020-09-18 |
WO2016145217A1 (en) | 2016-09-15 |
EA201791936A8 (ru) | 2018-11-30 |
SG11201707116QA (en) | 2017-09-28 |
US20180042991A1 (en) | 2018-02-15 |
EP3268024A4 (en) | 2018-08-01 |
MX2017011615A (es) | 2018-04-11 |
BR112017019294A2 (pt) | 2018-05-02 |
CA2978917A1 (en) | 2016-09-15 |
IL282053B (en) | 2022-11-01 |
IL282053A (en) | 2021-05-31 |
EP3268024B1 (en) | 2020-09-09 |
US20210069292A1 (en) | 2021-03-11 |
ES2836258T3 (es) | 2021-06-24 |
JP2018509164A (ja) | 2018-04-05 |
MX2023001213A (es) | 2023-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791936A8 (ru) | Рекомбинантные конструкции glut1 аденоассоциированного вирусного вектора и способы восстановления экспрессии glut1 на их основе | |
UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
CL2020002201A1 (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidación reducida de la cápside y usos de estos. | |
CL2022003757A1 (es) | Vectores de aav que tienen una desamidación reducida de la cápside y sus usos (divisional solic 202002200). | |
AR093355A1 (es) | Composiciones y metodos para tratar proteinopatias | |
CO2019009525A2 (es) | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este | |
PH12018500594A1 (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
NZ761655A (en) | Cellular models of and therapies for ocular diseases | |
WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
NZ726316A (en) | Adenoassociated virus vectors for the treatment of lysosomal storage disorders | |
AR109528A1 (es) | Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih | |
EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
EA201791971A1 (ru) | Онколитический аденовирус, кодирующий белок b7 | |
MX2022003857A (es) | Vectores del virus adenoasociado de b-sarcoglicano y microarn-29 y el uso de los mismos en la distrofia muscular. | |
MX2016006774A (es) | Vectores de virus adeno-asociado para el tratamiento de la enfermedad de almacenamiento de glucogeno. | |
PE20200722A1 (es) | Metodos de terapia genica del factor viii (fviii) | |
AR118850A1 (es) | Composiciones útiles en el tratamiento de leucodistrofia metacromática | |
EA202091712A1 (ru) | МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ | |
WO2014025771A3 (en) | Methods and compositions for inactivating enveloped viruses | |
MX2020000018A (es) | Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos. | |
EA201991041A1 (ru) | Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения | |
EA201790296A1 (ru) | Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9 | |
EA202290001A1 (ru) | Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута | |
EA201691807A1 (ru) | Лиофилизированные составы, содержащие фактор ix | |
EA202192543A1 (ru) | Вектор и способ для лечения синдрома ангельмана |